Clinical bottom line
Exosomal biomarkers, particularly exosomal microRNAs (miRNAs) and proteins, are emerging as promising non-invasive tools for cancer diagnosis, prognosis, and monitoring treatment response. These extracellular vesicles carry tumor-specific molecular cargo detectable in body fluids, offering potential advantages over traditional tissue biopsies. While accumulating evidence supports their diagnostic and prognostic utility across multiple cancer types—including breast, ovarian, and lung cancers—clinical translation remains limited by methodological heterogeneity and the need for standardized assays. Further large-scale validation studies are essential before routine clinical implementation (Alotaibi et al., 2020; Kiyanjam et al., 2022; Hsu et al., 2022).
What the evidence shows
Alotaibi et al. (2020) provide a comprehensive overview of exosomal miRNAs as biomarkers in cancer, highlighting their stability in circulation and ability to reflect tumor dynamics. They summarize studies demonstrating differential expression profiles of exosomal miRNAs in various malignancies, correlating with tumor stage, metastasis, and patient survival.
Kiyanjam et al. (2026) emphasize the role of exosomal miRNAs as liquid biopsy biomarkers for early cancer diagnosis and prognosis. Their review discusses advances in high-throughput sequencing and bioinformatics that enable identification of cancer-specific exosomal miRNA signatures, improving sensitivity and specificity compared to conventional markers.
Kiyanjam Mahnaz et al. (2022) focus on breast cancer, showing that exosomal miRNAs released from tumor cells serve as reliable non-invasive biomarkers for diagnosis and prognosis, with certain miRNAs correlating with chemoresistance and metastatic potential.
Hsu et al. (2022) extend the paradigm to exosomal proteins and lipids in lung cancer, demonstrating that specific exosomal cargo can discriminate early-stage disease and predict treatment response, supporting a multimodal biomarker approach.
Taylor and Douglas (2012, 2013) report on ovarian cancer, identifying distinct exosomal miRNA signatures associated with disease progression and survival, underscoring the potential for exosome-based assays to complement existing diagnostic modalities.
Caveats and uncertainty
Current studies vary widely in exosome isolation methods, miRNA/protein detection platforms, and patient cohorts, limiting comparability.
Most evidence derives from small, retrospective cohorts with limited external validation.
Biological heterogeneity of tumors and overlapping exosomal profiles with non-malignant conditions may reduce specificity.
Standardization of pre-analytical and analytical protocols is lacking, impeding clinical assay development.
Prospective trials demonstrating impact on clinical decision-making and patient outcomes are scarce.
How this may change practice
Exosomal biomarkers could supplement or partially replace invasive tissue biopsies, enabling earlier cancer detection and real-time monitoring of treatment efficacy.
Integration of exosomal miRNA and protein panels into liquid biopsy workflows may enhance diagnostic accuracy and prognostic stratification.
Personalized treatment regimens could be guided by dynamic changes in exosomal biomarker profiles.
Pathology laboratories will need to adopt standardized protocols and robust quality controls for exosome analysis.
Multidisciplinary collaboration between oncologists, pathologists, and molecular diagnostics experts will be critical for clinical translation.